Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.62 |
| ▸ | PLK4 | O00444 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 2/20 | 0.62 |
| ▸ | STK16 | O75716 | 2/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.62 |
| ▸ | FLT3 | P36888 | 2/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.62 |
| ▸ | MST1R | Q04912 | 2/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.62 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.62 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.62 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.62 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 0.62 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.62 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.62 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22068257 | 0.90 | SYK (0.69) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL12854262 | 0.86 | SYK (0.69) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL12212784 | 0.83 | SYK (0.66) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL12237025 | 0.83 | SYK (0.66) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL2627048 | 0.82 | SYK (0.72) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL4146597 | 0.80 | BRD4 (0.53) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL2523179 | 0.80 | SYK (0.70) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL655687 | 0.80 | SYK (0.64) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL655250 | 0.79 | SYK (0.53) | SYKADORA3TYRO3PLK4AURKA | |
| SCHEMBL29671171 | 0.79 | SYK (0.52) | SYKADORA3TYRO3PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3083648-B1 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | RIGEL PHARMACEUTICALS INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-1904457-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2011009075-A2 | DEUTERATED 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011009075-A2 | DEUTERATED 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | SYK 102/4885ADORA3 494/4885TYRO3 17/4885 |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | SYK 80/4885ADORA3 2808/4885TYRO3 122/4885 |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | SYK 80/4885ADORA3 2808/4885TYRO3 122/4885 |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | SYK 80/4885ADORA3 2808/4885TYRO3 122/4885 |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | SYK 80/4885ADORA3 2808/4885TYRO3 122/4885 |
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | DPYD, DUT, TYMP | SYK 2772/4885ADORA3 266/4885TYRO3 2582/4885 |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | SYK 80/4885ADORA3 2808/4885TYRO3 122/4885 |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | SYK 268/4885ADORA3 611/4885TYRO3 43/4885 |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | SYK 80/4885ADORA3 2808/4885TYRO3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.